Cargando…

The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma

This study aimed to explore the significance and prognostic value of serum tumor-associated carbohydrate antigen 19-9 (CA19-9), D-dimer, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20) in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included 148 patients treated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peng, Wang, XiaoDong, Qian, JianJun, Li, ZhengNan, Yao, Jie, Xu, AMan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545421/
https://www.ncbi.nlm.nih.gov/pubmed/33578593
http://dx.doi.org/10.1097/MD.0000000000024651
_version_ 1785114667737153536
author Xu, Peng
Wang, XiaoDong
Qian, JianJun
Li, ZhengNan
Yao, Jie
Xu, AMan
author_facet Xu, Peng
Wang, XiaoDong
Qian, JianJun
Li, ZhengNan
Yao, Jie
Xu, AMan
author_sort Xu, Peng
collection PubMed
description This study aimed to explore the significance and prognostic value of serum tumor-associated carbohydrate antigen 19-9 (CA19-9), D-dimer, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20) in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included 148 patients treated for PDAC at Northern Jiangsu People's Hospital Affiliated to Yangzhou University from January 2012 to December 2016. Cutoff prognostic values were predicted using the receiver operating characteristic (ROC) curve. The Kaplan–Meier method was used to assess the survival rates of patients. Univariate and multivariate COX regression analyses were used to evaluate the prognostic factors. The recommended cutoff values of neutrophil–lymphocyte rate (NLR), platelet-lymphocyte rate (PLR), CA19-9, and D-dimer were 2.04 (sensitivity, 0.59; specificity, 0.9; area under the ROC curve [AUC], 0.749; P < .001), 52.94 (sensitivity, 0.73; specificity, 0.95; AUC, 0.829; P < .001), 176.66 U/mL (sensitivity, 0.7; specificity, 0.9; AUC, 0.794; P < .001), and 1.18 mg/L (sensitivity, 0.82; specificity, 0.9; AUC, 0.845; P < .001), respectively. Positive TNFAIP3/A20 expression was considered as an inclusion criterion. Serum CA19-9 expression was related with lymph node metastasis (P = .010), tumor-lymph node-metastasis (TNM) stage (P < .001), and survival rate (P < .001). D-dimer was correlated with tumor differentiation grade (P = .014), tumor size (P = .045), TNM stage (P < .001), and survival rate (P < .001). TNFAIP3/A20 was correlated with tumor differentiation grade (P < .001), body mass index (BMI) (P < .001), TNM stage (P = .014), and survival rate (P < .001). Kaplan–Meier curves showed that PDAC patients had significant differences in CA19-9, D-dimer, and TNFAIP3/A20 expressions (P < .05). CA19-9, D-dimer, TNM stage, tumor differentiation grade, and TNFAIP3/A20 were independent prognostic markers for PDAC in univariate and multivariate COX analyses. CA19-9, D-dimer, and TNFAIP3/A20 were found to be independent prognostic markers for PDAC patients.
format Online
Article
Text
id pubmed-10545421
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105454212023-10-03 The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma Xu, Peng Wang, XiaoDong Qian, JianJun Li, ZhengNan Yao, Jie Xu, AMan Medicine (Baltimore) 5700 This study aimed to explore the significance and prognostic value of serum tumor-associated carbohydrate antigen 19-9 (CA19-9), D-dimer, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20) in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included 148 patients treated for PDAC at Northern Jiangsu People's Hospital Affiliated to Yangzhou University from January 2012 to December 2016. Cutoff prognostic values were predicted using the receiver operating characteristic (ROC) curve. The Kaplan–Meier method was used to assess the survival rates of patients. Univariate and multivariate COX regression analyses were used to evaluate the prognostic factors. The recommended cutoff values of neutrophil–lymphocyte rate (NLR), platelet-lymphocyte rate (PLR), CA19-9, and D-dimer were 2.04 (sensitivity, 0.59; specificity, 0.9; area under the ROC curve [AUC], 0.749; P < .001), 52.94 (sensitivity, 0.73; specificity, 0.95; AUC, 0.829; P < .001), 176.66 U/mL (sensitivity, 0.7; specificity, 0.9; AUC, 0.794; P < .001), and 1.18 mg/L (sensitivity, 0.82; specificity, 0.9; AUC, 0.845; P < .001), respectively. Positive TNFAIP3/A20 expression was considered as an inclusion criterion. Serum CA19-9 expression was related with lymph node metastasis (P = .010), tumor-lymph node-metastasis (TNM) stage (P < .001), and survival rate (P < .001). D-dimer was correlated with tumor differentiation grade (P = .014), tumor size (P = .045), TNM stage (P < .001), and survival rate (P < .001). TNFAIP3/A20 was correlated with tumor differentiation grade (P < .001), body mass index (BMI) (P < .001), TNM stage (P = .014), and survival rate (P < .001). Kaplan–Meier curves showed that PDAC patients had significant differences in CA19-9, D-dimer, and TNFAIP3/A20 expressions (P < .05). CA19-9, D-dimer, TNM stage, tumor differentiation grade, and TNFAIP3/A20 were independent prognostic markers for PDAC in univariate and multivariate COX analyses. CA19-9, D-dimer, and TNFAIP3/A20 were found to be independent prognostic markers for PDAC patients. Lippincott Williams & Wilkins 2021-02-12 /pmc/articles/PMC10545421/ /pubmed/33578593 http://dx.doi.org/10.1097/MD.0000000000024651 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 5700
Xu, Peng
Wang, XiaoDong
Qian, JianJun
Li, ZhengNan
Yao, Jie
Xu, AMan
The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
title The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
title_full The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
title_fullStr The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
title_full_unstemmed The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
title_short The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
title_sort prognostic evaluation of ca19-9, d-dimer and tnfaip3/a20 in patients with pancreatic ductal adenocarcinoma
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545421/
https://www.ncbi.nlm.nih.gov/pubmed/33578593
http://dx.doi.org/10.1097/MD.0000000000024651
work_keys_str_mv AT xupeng theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT wangxiaodong theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT qianjianjun theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT lizhengnan theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT yaojie theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT xuaman theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT xupeng prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT wangxiaodong prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT qianjianjun prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT lizhengnan prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT yaojie prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma
AT xuaman prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma